refractory/relapsed multiple myeloma research hub

Teclistamab plus autologous lymphocytes infusion for the treatment of relapsed/refractory Multiple Myeloma (TALIM). MM0125

This study looks at combining a new medicine, teclistamab, with a patient's own immune cells for multiple myeloma that has come back or not responded to other treatments. We want to see how long people stay well after this combined treatment.